Drugs / Mixtard 30:70
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02333851 | Jun 2013 → Feb 2014 | type 2 diabetes mellitus | Hospital Universitario Central de Asturias | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mixtard 30:70 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02333851 ↗ |
| Known as | Mixtard 30 | “Patients were randomized to receive a premixed human insulin formulation with 70% intermediate insulin plus 30% regular insulin (Mixtard 30®, Novo Nordisk) or a basal-bolus...” NCT02333851 ↗ |
| Modality | Protein / enzyme biologic | “premixed human insulin formulation” NCT02333851 ↗ |